drugset
drugset / Trial / NCT07412080

EDP167 in Healthy Volunteers and Subjects With Mild Dyslipidemia

NCT07412080 ↗

Phase 1 Completed 40 enrolled Eddingpharm (Zhuhai) Co., Ltd.
RandomizedSequentialQuadruple-blindTreatment

Summary

EDP167 is a double-stranded small interfering RNA (siRNA) drug targeting ANGPTL3, which may bring benefits for patients with dyslipidemia conditions. This is the first in human study of EDP167 in health volunteers and subjects with mild dyslipidemia to evaluate the safety and PK/PD profiles of EDP167.

Timeline

Start
2025-07-01
Primary completion
2025-12-12
Completion
2025-12-12

Drugs

EvaluationDrugModalityDoseRoute
Subject EDP167 Small interfering RNA (siRNA) 35 mg Subcutaneous
Subject EDP167 Small interfering RNA (siRNA) 100 mg Subcutaneous
Subject EDP167 Small interfering RNA (siRNA) 200 mg Subcutaneous
Subject EDP167 Small interfering RNA (siRNA) 300 mg Subcutaneous
Subject EDP167 Small interfering RNA (siRNA) 400 mg Subcutaneous

Indications

No indication recorded.